TheStreet restated their buy rating on shares of Merck & Co (NYSE:MRK) in a report issued on Monday, American Banking News reports.
“Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.,” the firm’s analyst commented.
Other equities research analysts have also recently issued reports about the stock. Analysts at BMO Capital Markets raised their price target on shares of Merck & Co from $50.00 to $54.00 in a research note to investors on Tuesday, November 26th. Finally, analysts at Argus reiterated a buy rating on shares of Merck & Co in a research note to investors on Wednesday, October 30th. They now have a $54.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company’s stock. Merck & Co has an average rating of Hold and a consensus price target of $51.67.
Shares of Merck & Co (NYSE:MRK) traded down 0.42% during mid-day trading on Monday, hitting $49.35. 2,017,830 shares of the company’s stock traded hands. Merck & Co has a 52 week low of $40.02 and a 52 week high of $50.42. The stock has a 50-day moving average of $47.54 and a 200-day moving average of $47.67. The company has a market cap of $144.2 billion and a price-to-earnings ratio of 33.31.
Merck & Co (NYSE:MRK) last announced its earnings results on Monday, October 28th. The company reported $0.92 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.88 by $0.04. The company had revenue of $11.03 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The company’s quarterly revenue was down 4.0% on a year-over-year basis. Analysts expect that Merck & Co will post $3.50 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, January 8th. Shareholders of record on Monday, December 16th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 3.55%. The ex-dividend date is Thursday, December 12th. This is a positive change from Merck & Co’s previous quarterly dividend of $0.43.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.